Radiotherapy Controversies and Prospective in Head and Neck Cancer: A Literature-Based Critical Review

Overview

Journal Neoplasia

Publisher Elsevier

Specialty Oncology

Date 2018 Feb 16

PMID 29448084

Citations 23

Authors

Francesca De Felice

Antonella Polimeni

Valentino Valentini

Orlando Brugnoletti

Andrea Cassoni

Antonio Greco

Marco de Vincentiis

Vincenzo Tombolini

Affiliations

Soon will be listed here.

Abstract

In treating head and neck cancer (HNC), the objectives are provided for best functional results and minimal risk of serious complications. The choice of appropriate management depends primarily on specific site and stage of primary tumor at diagnosis. Radiation therapy (RT) with or without concomitant chemotherapy represents a classical treatment option. In this review, we provide an update of recent research strategies to counteract the existing damage caused by RT and highlight clinical trials currently in progress. We discuss the challenges in the evaluation of new stage system and RT-related toxicity onset. We mainly address the deficiencies and the advantages noted in the current treatment era.

Citing Articles

Evaluation of Interfractional Setup Uncertainties and Calculation of Adequate CTV-PTV Margin for Head and Neck Radiotherapy using Electronic Portal Imaging Device.

Ahmadi E, Eskandari A, Mohammadi M, Naji M, Naseri S, Gholamhosseinian H J Biomed Phys Eng. 2025; 15(1):5-14.

PMID: 39975521 PMC: 11833158. DOI: 10.31661/jbpe.v0i0.2211-1565.

Assessment of multispecies biofilm growth on root canal dentin under different radiation therapy regimens.

Goulart T, Hawerroth T, Teixeira C, Cesca K, Silva R, de Moraes R Clin Oral Investig. 2024; 28(6):324.

PMID: 38761225 DOI: 10.1007/s00784-024-05719-x.

A real-world evaluation of tislelizumab in patients with head and neck cancer.

Zheng B, Huang Z, Liu W, Zhao D, Xu X, Xiao S Transl Cancer Res. 2024; 13(2):808-818.

PMID: 38482433 PMC: 10928599. DOI: 10.21037/tcr-23-1502.

Trehalose versus carboxymethylcellulose oral spray for relieving radiation-induced xerostomia in head and neck cancer patients: a randomized controlled trial.

Piboonratanakit P, Ferreira J, Pravinvongvuthi K, Maison K, Urkasemsin G, Boonroung T BMC Oral Health. 2023; 23(1):288.

PMID: 37179287 PMC: 10182540. DOI: 10.1186/s12903-023-02966-4.

Induction Therapy With Cisplatin, 5-Fluorouracil, Leucovorin, and Paclitaxel in Patients With Head and Neck Cancer.

Eduardo Coelho de Sa C, Cubero D, da Costa R, DI Pardo R, Silva Melo Cruz F, Vaz de Melo Sette C In Vivo. 2023; 37(3):1339-1345.

PMID: 37103110 PMC: 10188017. DOI: 10.21873/invivo.13215.

References

Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I . Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007; 52(16):5025-42. DOI: 10.1088/0031-9155/52/16/021. View

Lydiatt W, Patel S, OSullivan B, Brandwein M, Ridge J, Migliacci J . Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(2):122-137. DOI: 10.3322/caac.21389. View

Lacas B, Bourhis J, Overgaard J, Zhang Q, Gregoire V, Nankivell M . Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017; 18(9):1221-1237. PMC: 5737765. DOI: 10.1016/S1470-2045(17)30458-8. View

De Felice F, Musio D, Tombolini V . Mastication structures definition in head and neck cancer. Radiother Oncol. 2016; 118(2):419. DOI: 10.1016/j.radonc.2015.12.016. View

Cooks T, Tal M, Raab S, Efrati M, Reitkopf S, Lazarov E . Intratumoral 224Ra-loaded wires spread alpha-emitters inside solid human tumors in athymic mice achieving tumor control. Anticancer Res. 2012; 32(12):5315-21. View

Kumar S . Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health. 2012; 9(12):4744-59. PMC: 3546788. DOI: 10.3390/ijerph9124744. View

Cooks T, Arazi L, Schmidt M, Marshak G, Kelson I, Keisari Y . Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer. 2007; 122(7):1657-64. DOI: 10.1002/ijc.23268. View

De Felice F, Musio D, Tombolini V . Osteoradionecrosis: an old toxicity in the IMRT era?. Oral Oncol. 2015; 51(6):e60-1. DOI: 10.1016/j.oraloncology.2015.03.002. View

Brouwer C, Steenbakkers R, Bourhis J, Budach W, Grau C, Gregoire V . CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol. 2015; 117(1):83-90. DOI: 10.1016/j.radonc.2015.07.041. View

10.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

11.

Weber D, Abrunhosa-Branquinho A, Bolsi A, Kacperek A, Dendale R, Geismar D . Profile of European proton and carbon ion therapy centers assessed by the EORTC facility questionnaire. Radiother Oncol. 2017; 124(2):185-189. DOI: 10.1016/j.radonc.2017.07.012. View

12.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

13.

Marur S, Li S, Cmelak A, Gillison M, Zhao W, Ferris R . E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2016; 35(5):490-497. PMC: 5455313. DOI: 10.1200/JCO.2016.68.3300. View

14.

Zhang W, Zhang X, Yang P, Blanchard P, Garden A, Gunn B . Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer. Radiother Oncol. 2017; 123(3):401-405. PMC: 5779856. DOI: 10.1016/j.radonc.2017.05.006. View

15.

Ng W, Lee M, Chang A, Chan O, Chan L, Cheung F . The impact of dosimetric inadequacy on treatment outcome of nasopharyngeal carcinoma with IMRT. Oral Oncol. 2014; 50(5):506-12. DOI: 10.1016/j.oraloncology.2014.01.017. View

16.

Good J, Harrington K . The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Oncol (R Coll Radiol). 2013; 25(10):569-77. DOI: 10.1016/j.clon.2013.06.009. View

17.

Rosenthal D, Chambers M, Fuller C, Rebueno N, Garcia J, Kies M . Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer. Int J Radiat Oncol Biol Phys. 2008; 72(3):747-55. PMC: 9627578. DOI: 10.1016/j.ijrobp.2008.01.012. View

18.

Nutting C, Morden J, Harrington K, Urbano T, Bhide S, Clark C . Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2):127-36. PMC: 3033533. DOI: 10.1016/S1470-2045(10)70290-4. View

19.

De Felice F, Musio D, Tombolini V . Osteoradionecrosis and intensity modulated radiation therapy: An overview. Crit Rev Oncol Hematol. 2016; 107:39-43. DOI: 10.1016/j.critrevonc.2016.08.017. View

20.

Formenti S, Demaria S . Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013; 105(4):256-65. PMC: 3576324. DOI: 10.1093/jnci/djs629. View